EP1036088A1 - Method of preparing 16 alpha,17 alpha-dialkylated steroids - Google Patents

Method of preparing 16 alpha,17 alpha-dialkylated steroids

Info

Publication number
EP1036088A1
EP1036088A1 EP98956638A EP98956638A EP1036088A1 EP 1036088 A1 EP1036088 A1 EP 1036088A1 EP 98956638 A EP98956638 A EP 98956638A EP 98956638 A EP98956638 A EP 98956638A EP 1036088 A1 EP1036088 A1 EP 1036088A1
Authority
EP
European Patent Office
Prior art keywords
silyl ether
alkyl
dialkylated
enol silyl
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98956638A
Other languages
German (de)
French (fr)
Inventor
Raymond E. Conrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of EP1036088A1 publication Critical patent/EP1036088A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)

Definitions

  • the present invention relates to methods of synthesizing 16 ⁇ ,17 ⁇ - dialkylated steroids.
  • the present invention relates to methods of appending a 17 ⁇ -alkyl substituent to a steroidal 16 ⁇ -alkyl-17(20)-enyl-20-silyl ether.
  • 16 ⁇ ,17 ⁇ -dialkylated steroids have desirable medicinal properties. See, for example, U.S. Patent No. 4,686,214; Cairns, et al., J. Chem. Soc, Perkin Trans. I, 1981 :2306, and references cited therein.
  • the one-step conjugate addition-enolate trapping method sometimes gives the desired 16 ⁇ ,17 ⁇ -dialkylated steroid in low yield and contaminated with polyalkylated side products.
  • Such side products can be difficult to remove using conventional purification techniques, e.g., recrystallization: Cairns, et al., J. Chem. Soc, Perkin Trans. I, 1981 :2306 and 1978:1594.
  • steroidal 16 ⁇ -alkyl-17(20)-enyl-20- silyl ethers are reacted with an enol silyl ether cleaving agent and an alkylating agent to give the corresponding 16 ⁇ ,17 ⁇ -dialkylated steroid.
  • Enones of Formula I are known.
  • the compounds of Formula I can be prepared, for example, according to the methods cited or disclosed in commonly assigned, co-pending Patent Application No. PCT/US97/19276, titled “METHOD OF PREPARING 21-ALKYLATED PREGNA-1 ,4,16-TRIEN- 3,20-DIONES,” filed October 22, 1997, which claims priority from parent U.S. provisional application serial no. 60/029,312, filed October 25, 1996.
  • R 1 is H or CHR 4 R 5 ;
  • Y is H, F, or Cl; or X and Y taken together are a covalent bond; or X and Y taken together form an epoxide group:
  • R 4 , R 5 and R 6 are independently H or C, - C 4 alkyl; R 7 , R 8 and R 9 are independently C 1 - C 4 alkyl; and Q is H or CH,
  • Enol silyl ethers of Formula II can be prepared by addition of a stoichiometric organocuprate reagent and a silylating agent to enones of Formula I, as described in Example 1 below.
  • a catalytic organocuprate reagent can be used, as described by Horiguchi et al., Org. Synth., 73:123 (1995) for the case of copper-catalyzed Grignard addition to 16-dehydroprogesterone.
  • Appropriate temperatures will be determined by those skilled in the art, but will typically range from 0 to -100 °C. In most instances, it is expected that temperatures ranging from -20 to -80 °C will be sufficient for the organocuprate addition reaction to selectively produce the intended product.
  • R 2 is C., - C 4 alkyl, and is most preferably CH 3 ; and X, Y, Q, R ⁇ R 7 , R 8 , and R 9 are as defined above.
  • Preferred compounds of Formula II are those where R 1 is CH 3 ; R 2 is CH 3 ; Q and Y are H; X is OSiR 7 R 8 R 9 and R 7 , R 8 , and R 9 are CH 3
  • enol silyl ethers of Formula II are reacted in a suitable solvent with an alkylating agent, R 3 CH 2 Z, and an enol silyl ether cleaving agent to give the corresponding 16 ⁇ ,17 ⁇ - dialkylated steroid of Formula III.
  • X, Y, Q, R 1 , and R 2 are as defined above.
  • the alkylating agents, R 3 CH 2 Z, suitable for use in the methods of the present invention are known compounds.
  • R 3 is selected from the group consisting of hydrogen, an alkyl group of up to three carbon atoms total, an ethenyl group, an ethynyl group, and a phenyl group.
  • R 3 is H.
  • Z is Cl, Br or I, and is preferably I.
  • the enol silyl ether cleaving agent is selected from the group consisting of a fluoride salt and lithium amide.
  • a third type of known enol silyl ether cleaving agents, alkyllithium compounds, is not suitable for use in the methods of the present invention because such compounds preferentially react with the 3-keto group rather than the 17(20)-enyl-20-silyl ether.
  • the fluoride salt is preferably a tetraalkylammonium fluoride compound.
  • An especially preferred fluoride salt is benzyltrimethylammonium fluoride.
  • Suitable solvents for use with the fluoride salt embodiment of the present invention include tetrahydrofuran ("THF") and glyme. The preferred solvent for use with a fluoride salt is THF.
  • the alkylation reaction is preferably conducted in the presence of a suitable drying agent, such as zeolite molecular sieves (see Kuwajima, et al., J. Am. Chem. Soc, 104:1025 (1982)).
  • a suitable drying agent such as zeolite molecular sieves (see Kuwajima, et al., J. Am. Chem. Soc, 104:1025 (1982)).
  • lithium amide is chosen as the enol silyl ether cleaving agent
  • the preferred solvent is liquid ammonia.
  • Lithium hexamethyldisilazide (estimated 0.9 M in THF, 2.1 mL, 1.9 mmol) was added over 8 min. to a stirred, cooled (-60 to -65 °C internal) solution of 11 ⁇ - (trimethylsiloxy)-pregna-1 ,4,16-trien-3,20-dione (0.73 g, 1.83 mmol) in THF (12.0 mL) and HMPA (3.0 mL) under Ar. After a further 2 min, the cloudy pale-orange mixture was quenched rapidly with iodomethane (2.5 mL, 40 mmol) whereupon the temperature rose to -57 °C and the suspension cleared.
  • iodomethane 2.5 mL, 40 mmol

Abstract

16α,17α-Dialkylated steroids are prepared by reacting a 16α-alkyl-17(20)-enyl-20-silyl ether with an alkylating agent and an enol silyl ether cleaving agent in a suitable solvent.

Description

METHOD OF PREPARING 16α,17α-DIALKYLATED STEROIDS
FIELD OF THE INVENTION
The present invention relates to methods of synthesizing 16α,17α- dialkylated steroids. In particular, the present invention relates to methods of appending a 17α-alkyl substituent to a steroidal 16α-alkyl-17(20)-enyl-20-silyl ether.
BACKGROUND OF THE INVENTION
16α,17α-dialkylated steroids have desirable medicinal properties. See, for example, U.S. Patent No. 4,686,214; Cairns, et al., J. Chem. Soc, Perkin Trans. I, 1981 :2306, and references cited therein.
Previous syntheses of 16α,17α-dialkylated steroids have employed a one-step conjugate addition-enolate trapping method to accomplish the addition of the C16 and C17 alkyl groups. For example, see Schaub, et al., J. Med. Chem., 10:789 (1967), and Cairns, et al., J. Chem. Soc, Perkin Trans. I, 1978:1594 and 1976:1558, disclosing alkyl Grignard conjugate addition reaction followed by an alkyl halide quench in a single reaction vessel.
The one-step conjugate addition-enolate trapping method sometimes gives the desired 16α,17α-dialkylated steroid in low yield and contaminated with polyalkylated side products. Such side products can be difficult to remove using conventional purification techniques, e.g., recrystallization: Cairns, et al., J. Chem. Soc, Perkin Trans. I, 1981 :2306 and 1978:1594.
Alternative methods of preparing 16α, 17α-dialkylated steroids are desired. SUMMARY OF THE INVENTION
According to the present invention, steroidal 16α-alkyl-17(20)-enyl-20- silyl ethers are reacted with an enol silyl ether cleaving agent and an alkylating agent to give the corresponding 16α,17α-dialkylated steroid.
DETAILED DESCRIPTION OF THE INVENTION
Enones of Formula I are known. The compounds of Formula I can be prepared, for example, according to the methods cited or disclosed in commonly assigned, co-pending Patent Application No. PCT/US97/19276, titled "METHOD OF PREPARING 21-ALKYLATED PREGNA-1 ,4,16-TRIEN- 3,20-DIONES," filed October 22, 1997, which claims priority from parent U.S. provisional application serial no. 60/029,312, filed October 25, 1996.
(I)
wherein R1 is H or CHR4R5; X is OSiR7R8R9 or OC(=O)R6;
Y is H, F, or Cl; or X and Y taken together are a covalent bond; or X and Y taken together form an epoxide group:
R4, R5 and R6 are independently H or C, - C4 alkyl; R7, R8 and R9 are independently C1 - C4 alkyl; and Q is H or CH,
Enol silyl ethers of Formula II can be prepared by addition of a stoichiometric organocuprate reagent and a silylating agent to enones of Formula I, as described in Example 1 below. Alternatively, a catalytic organocuprate reagent can be used, as described by Horiguchi et al., Org. Synth., 73:123 (1995) for the case of copper-catalyzed Grignard addition to 16-dehydroprogesterone. Generally, it is desirable to conduct this addition reaction at low temperatures to increase the yield of the intended alkylation product. Appropriate temperatures will be determined by those skilled in the art, but will typically range from 0 to -100 °C. In most instances, it is expected that temperatures ranging from -20 to -80 °C will be sufficient for the organocuprate addition reaction to selectively produce the intended product.
wherein R2 is C., - C4 alkyl, and is most preferably CH3; and X, Y, Q, R\ R7, R8, and R9 are as defined above.
Preferred compounds of Formula II are those where R1 is CH3; R2 is CH3; Q and Y are H; X is OSiR7R8R9 and R7, R8, and R9 are CH3
According to the methods of the present invention, enol silyl ethers of Formula II are reacted in a suitable solvent with an alkylating agent, R3CH2Z, and an enol silyl ether cleaving agent to give the corresponding 16α,17α- dialkylated steroid of Formula III. Subsequently, the protecting group at the 11 -position can be removed ((OSiR7R8R9 or OC(=0)R6) → OH) using known methods (e.g., U.S. Patent No. 4,012,510 and Cairns, et al., J. Chem. Soc, Perkin Trans. I, 1981 :2306), to obtain a medicinally useful 16α,17α- dialkylated steroid.
(III)
wherein R3 is H, C, - C3 alkyl, C≡CH, CH=CH2, or phenyl; and
X, Y, Q, R1, and R2 are as defined above.
The general chemical methodology involved is known for other applications. See Kuwajima, et al., J. Am. Chem. Soc, 104:1025 (1982) (fluoride salt method); Patterson, et al., J. Org. Chem., 39:2506 (1974) and Binkley, et al., J. Org. Chem., 40:2156 (1975) (lithium amide method). According to these references, such methods result in little formation of polyalkylated side products.
The alkylating agents, R3CH2Z, suitable for use in the methods of the present invention are known compounds. R3 is selected from the group consisting of hydrogen, an alkyl group of up to three carbon atoms total, an ethenyl group, an ethynyl group, and a phenyl group. Preferably, R3 is H. Z is Cl, Br or I, and is preferably I. The enol silyl ether cleaving agent is selected from the group consisting of a fluoride salt and lithium amide. A third type of known enol silyl ether cleaving agents, alkyllithium compounds, is not suitable for use in the methods of the present invention because such compounds preferentially react with the 3-keto group rather than the 17(20)-enyl-20-silyl ether.
In the event that a fluoride salt is chosen as the enol silyl ether cleaving agent, the fluoride salt is preferably a tetraalkylammonium fluoride compound. An especially preferred fluoride salt is benzyltrimethylammonium fluoride. Suitable solvents for use with the fluoride salt embodiment of the present invention include tetrahydrofuran ("THF") and glyme. The preferred solvent for use with a fluoride salt is THF. In the case of a fluoride salt enol silyl ether cleaving agent, the alkylation reaction is preferably conducted in the presence of a suitable drying agent, such as zeolite molecular sieves (see Kuwajima, et al., J. Am. Chem. Soc, 104:1025 (1982)).
If lithium amide is chosen as the enol silyl ether cleaving agent, the preferred solvent is liquid ammonia. A cosolvent, such as THF, is optionally employed.
The following examples are presented to illustrate further various aspects of the present invention, but are not intended to limit the scope of the invention in any respect.
EXAMPLE 1
Preparation of 16α,21 -Dimethy 1-11 β,20-bis(trimethylsiloxy)-pregna-1 ,4,17(20)-trien-3- one
a) Preparation of dilithium dimethyl(cyano)cuprate(l). Methyllithium (1.0 M in 9:1 cumene-THF, 4.0 mL, 4.0 mmol) was added dropwise via syringe over 5 min to a stirred, ice-cooled suspension of CuCN powder (187 mg, 2.09 mmol) in anhydrous THF (6.0 mL) under Ar, giving a clear, pale pink-purple solution of Me2Cu(CN)Li2 (0.2 M).
b) Preparation of Pregna-1,4,16-trien-11β-ol-3,20-dione. i) The method of Kovendi et al., Rev. Chim. (Bucharest), 27:467
(1976) was modified. Semicarbazide hydrochloride (7.1 mL of a 5% aq. solution, 3.2 mmol) was added to a stirred, 50 °C solution of 21- deoxyprednisolone (1.82 g, 5.29 mmol) [see U.S. Patent No. 3,033,873 and Vitali et al., Gazz. Chim. Ital., 96:1115 (1966)] in acetic acid (60 mL) under Ar. The solution was heated to 75-80 °C (internal). After 2.7 h, another 4.7 mL of 5% aq. semicarbazide hydrochloride (2.1 mmol) was added. After 5.5 h at 75 °C, water (50 mL) was added and the solution was heated to 75 °C for 10 h and then to 90 °C for 1.5 h. The solution was cooled to room temperature, poured into 600 mL of water, stirred for 1 h, diluted with water to 1 L, stirred for 0.5 h and filtered on a fritted Buchner funnel. The solid was dried at 80 °C for 3-4 h to a constant weight of 1.00 g (58%, nominal) of crude product, C21H26O3.
Proton NMR (CDCI3): d 1.22 (s, 3H, I8-H3); 1.48 (s, 3H, 19-Hβ), 2.27 (s, 3H, 21-H3); 1.0-2.7 (m, 12H); 4.38 (br q, 1H, J=2.5, H-11); 6.00 (s, 1 H, H-4); 6.25 (dd, 1 H, J=10 and 2, H-2); 6.66 (q, 1H, J=2, H-16); 7.32 (d, 1H, J=10, H-1).
This material was converted in 75% yield to the known trimethylsilyl derivative, 11β-(trimethylsiloxy)-pregna-1 ,4,16-trien-3,20-dione (Formula I where X = OSi(CH3)3; Y = Q = H), as described in U.S. Patent No. 4,012, 510.
ii) The method of Kovendi et al., Rev. Chim. (Bucharest), 27:467 (1976) was modified. Semicarbazide hydrochloride (4.75 mL of a 5.0 % aq. solution, 2.14 mmol) was added to a stirred solution of 21-deoxyprednisolone (2.15 g, 6.25 mmol) [see U.S. Patent No. 3,033,873 and Vitali et al., Gazz. Chim. Ital., 96:1115 (1966)] in acetic acid (72 mL) under Ar. The solution was heated to 80-85 °C (bath) for 4.2 h. Water (75 mL) was added and heating (85 °C bath) was continued for 5.5 h. The solution was cooled to 23 °C over 11 h, poured into water (850 mL), cooled in ice (to 7 °C) and filtered on a fritted Buchner funnel. The solid was dried under vacuum to give 1.40 g (69%, nominal) of crude product, C21H26O3.
Proton NMR (CDCI3): d 1.22 (s, 3H, I8-H3); 1.48 (s, 3H, 19-H3), 2.27 (s, 3H, 21-H3); 1.0-2.7 (m, 12H); 4.38 (br q, 1 H, J=2.5, H-11); 6.00 (s, 1 H, H-4); 6.25 (dd, 1H, J=10 and 2, H-2); 6.66 (q, 1 H, J=2, H-16); 7.32 (d, 1 H, J=10, H-1).
This material was converted in 83% yield to the known trimethylsilyl derivative, 11 β-(trimethylsiloxy)-pregna-1 ,4,16-trien-3,20-dione (Formula I where X = OSi(CH3)3; Y = Q = H), as described in U.S. Patent No. 4,012, 510.
c) Preparation of 21 -Methy 1-11 β-(trimethylsiloxy)-pregna-1 ,4,16-trien- 3,20-dione.
Lithium hexamethyldisilazide (estimated 0.9 M in THF, 2.1 mL, 1.9 mmol) was added over 8 min. to a stirred, cooled (-60 to -65 °C internal) solution of 11β- (trimethylsiloxy)-pregna-1 ,4,16-trien-3,20-dione (0.73 g, 1.83 mmol) in THF (12.0 mL) and HMPA (3.0 mL) under Ar. After a further 2 min, the cloudy pale-orange mixture was quenched rapidly with iodomethane (2.5 mL, 40 mmol) whereupon the temperature rose to -57 °C and the suspension cleared. The solution was warmed over 2 min to 10 °C, quenched with sat. KH2PO4, and partitioned with EtOAc. The organic solution was dried (MgSO4), filtered and concentrated. The residue (1.9 g) was purified by chromatography (80 g silica, 25% to 50% EtOAc-hexanes) to give 0.62 g (82%) of the product, C25H36θ3Si, as an off-white solid, m.p. 178 - 182 °C (dec).
Proton NMR (CDCI3): d 0.24 (s, 9H, Me3Si); 1.05 (t, 3H, J=7.3, Me-21); 1.18 (s, 3H, I8-H3); 1.41 (s, 3H, 19-H3); 1.0 - 2.8 (m, 11 H); 2.6 (q, 2H, 21-H2); 4.37 (br q, 1H, J=2.5, H-11); 5.99 (s, 1 H, H-4); 6.25 (dd, 1 H, J=10 and 2, H- 2); 6.64 (q, 1H, J=2, H-16); 7.12 (d, 1H, J=10, H-1).
d) Addition.
To a stirred, cooled (-45 °C bath, MeCN-CO2) solution of 21-methyl-11β- (trimethylsiloxy)-pregna-1 ,4,16-trien-3,20-dione (0.395 g, 0.96 mmol) in 9.0 mL of anhydrous THF under Ar was added via syringe chlorotrimethylsilane (0.50 mL, 4.0 mmol), followed by dropwise addition over 3 min of 5.0 mL (1.0 mmol) of the above cuprate solution. After 10 min, the mixture was quenched at -45 °C (bath) by rapid addition via syringe of a solution of 0.5 mL (12 mmol) of MeOH and 1.5 mL (11 mmol) of Et3N and warming to 0 °C. Water and EtOAc were added and the solution was stirred vigorously. The pH was adjusted from 9 to 7 with sat. KH2PO4 and stirring was continued for 0.5 h. The layers were separated and the organic solution was washed with water and brine, dried (MgSO4), filtered and concentrated. The residue was purified by chromatography to give 0.41 g (85.5%) of the desired product, C29H48θ3Si2, as a white solid.
Proton NMR (CDCI3): d 0.20 (s, 9H, Me3Si); 0.24 (s, 9H, Me3Si); 0.96 (d, 3H, J = 6.9, Me-16); 1.01 (t, 3H, J = 7.4, Me-21); 1.07 (s, 3H, I8-H3); 1.39 (s, 3H, 19-H3); 0.9-2.4 (m); 2.6 (br m, 3H, 20-H2 and H-16); 4.38 (br s, 1H, H- 11); 6.01 (s, 1 H, H-4); 6.28 (dd, 1H, J = 10 and 2); 7.12 ( d, 1 H, J = 10).
Example 2
Preparation of 11 β-(Trimethylsiloxy)-16α,17α,21 -trimethy lpregna-1 ,4-dien-3,20-dione
(a). Preparation of reagents. A 3 gram sample of benzyltrimethylammonium fluoride hydrate was dried at 55 °C /0.2 Torr (Abderhalden, MeOH) for 40 h, then transferred under Ar to an Ar-filled desiccator over P2O5. Molecular sieves (4A, 1/16 in. spheres) were dried at 250 °C (internal) for several hours and cooled in the desiccator, lodomethane was dried over 4A molecular sieves.
(b). Alkylation. Molecular sieves (2.7 g) and benzyltrimethylammonium s fluoride (0.8 g) were weighed under Ar (glove bag) into an oven-dried (100 °C) 25-mL 2-neck round bottom flask containing a magnetic stir bar. THF (3.0 mL, freshly distilled from a potassium-benzophenone solution under Ar) was added via syringe and the mixture was stirred rapidly under Ar for 6 h. To the resulting paste was added via syringe a solution of 16α,21-dimethyl-11 β,20- o bis(trimethylsiloxy)-pregna-1,4,17(20)-trien-3-one (47 mg, 0.094 mmol) in iodomethane (1.3 mL, 21 mmol). The mixture was stirred for 45 min at rt. Ethyl acetate was added and the suspension was filtered, rinsing well with ethyl acetate. The filtrate was washed with half-saturated brine, dried (MgSO4), filtered through a pad of Florisil with EtOAc and concentrated to is give 46.5 mg of an oil that solidified on standing. Crystallization from 12% EtOAc-hexanes (6 mL) at -25 °C followed by drying under vacuum at 75 °C afforded 26 mg (63%) of a white solid, C27H42O3S
Proton NMR (CDCI3): d 0.20 (s, 9H, Me3Si); 0.87 (d, 3H, J=7.2, Me-16); 0.94 20 (s, 6H, Me-17+18-H3); 1.04 (t, 3H, J=7.1 , Me-21); 1.37 (s, 3H, 19-H3); 2.34 (q, 2H, J=7, 21-H2); 1.1-2.7 (m); 3.07 (m, 1 H, H-16); 4.46 (br t, 1 H, J=3, H- 11); 6.00 (s, 1H, H-4); 6.27 (dd, 1H, J=10 and 2, H-2); 7.10 (d, 1H, J=10, H-
1)-
The invention has been described by reference to certain preferred
25 embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing
30 description.

Claims

WHAT IS CLAIMED IS:
1. A method of preparing a 16╬▒,17╬▒-dialkylated steroid of the formula
wherein R1 is H or CHR4R5; R2 is C, - C4 alkyl;
R3 is H, C, - C3 alkyl, CΓëíCH, CH=CH2, or phenyl; X is OSiR7R8R9 or OC(=O)R6; Y is H, F, or Cl; or X and Y taken together are a covalent
R4, R5 and R6 are independently H or C, - C4 alkyl; R7, R8 and R9 are independently C., - C4 alkyl; and Q is H or CH3;
comprising reacting in a solvent an enol silyl ether of the formula
with an enol silyl ether cleaving agent and an alkylating agent of the formula R3CH2Z
wherein R3 is selected from the group consisting of hydrogen, a Z is CI, Br or l.
2. The method of Claim 1 wherein R1 is CH3; R2 is CH3; Q and Y are H; X is OSiR7R8R9 and R7, R8, and R9 are CH3.
3. The method of Claim 1 wherein R3 is H and Z is I.
4. The method of Claim 1 wherein the enol silyl ether cleaving agent is selected from the group consisting of a fluoride salt and lithium amide.
5. The method of Claim 4 wherein the enol silyl ether cleaving agent is a tetraalkylammonium fluoride salt.
6. The method of Claim 5 wherein the enol silyl ether cleaving agent is benzyltrimethylammonium fluoride.
7. The method of Claim 5 wherein the solvent is selected from the group consisting of tetrahydrofuran and glyme.
8. The method of Claim 7 wherein the solvent is tetrahydrofuran.
9. The method of Claim 4 wherein the enol silyl ether cleaving agent is lithium amide and the solvent is liquid ammonia.
EP98956638A 1997-12-02 1998-11-05 Method of preparing 16 alpha,17 alpha-dialkylated steroids Ceased EP1036088A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6714897P 1997-12-02 1997-12-02
US67148P 1997-12-02
PCT/US1998/023641 WO1999028336A1 (en) 1997-12-02 1998-11-05 METHOD OF PREPARING 16α,17α-DIALKYLATED STEROIDS

Publications (1)

Publication Number Publication Date
EP1036088A1 true EP1036088A1 (en) 2000-09-20

Family

ID=22074020

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98956638A Ceased EP1036088A1 (en) 1997-12-02 1998-11-05 Method of preparing 16 alpha,17 alpha-dialkylated steroids

Country Status (7)

Country Link
EP (1) EP1036088A1 (en)
JP (1) JP2001525333A (en)
AR (1) AR017423A1 (en)
AU (1) AU737219B2 (en)
BR (1) BR9814717A (en)
CA (1) CA2299396A1 (en)
WO (1) WO1999028336A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263213B1 (en) * 1986-10-09 1995-09-06 The Upjohn Company C20 Through C26 amino steroids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9928336A1 *

Also Published As

Publication number Publication date
AR017423A1 (en) 2001-09-05
WO1999028336A1 (en) 1999-06-10
CA2299396A1 (en) 1999-06-10
JP2001525333A (en) 2001-12-11
BR9814717A (en) 2000-10-03
AU737219B2 (en) 2001-08-09
AU1311599A (en) 1999-06-16

Similar Documents

Publication Publication Date Title
AU2008269531B2 (en) Industrial method for the synthesis of 17-acetoxy-11beta-[4-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process
JPH0369919B2 (en)
US6072068A (en) 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives
EP0189951B1 (en) New process for the preparation of certain steroids, especially intermediates for the preparation of proligestone and related compounds, and new intermediates formed in this process
HU209783B (en) Process for the production of 17-cyano-androsten-17-(halo-alkyl-sylil)-ethers
EP1242444B1 (en) Process for preparing 17alpha-acetoxy-11beta- 4-n,n-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates
EP0291717B1 (en) 17beta-(cyclopropyloxy) androst-5-en-3beta-ol and related compounds useful as c 17-20 lyase inhibitors
US4267106A (en) New process for the preparation 17β-hydroxy-3-oxo-17α-pregnene and pregnadiene-21-carboxylic acid γ-lactones
JPH0649717B2 (en) Novel steroids substituted at the 10-position with a group containing a double bond or a triple bond, their production method and drug
US6040468A (en) Method of preparing 16α, 17α-dialkylated steroids
EP1036088A1 (en) Method of preparing 16 alpha,17 alpha-dialkylated steroids
US5438134A (en) Process for the production of unsaturated 17 α-cyanomethyl-17 β-h
HU221161B1 (en) 3-oxo delta4,9-steroids and process for producing them
Peters et al. Steroidal silicon side-chain analogs as potential antifertility agents
RU2305105C2 (en) METHOD FOR PREPARING 7α-METHYLSTEROIDS, COMPOUND
MXPA00005365A (en) METHOD OF PREPARING 16&agr;,17&agr;-DIALKYLATED STEROIDS
US4582644A (en) Epi-ethynylation process
US20040010138A1 (en) Process for the production of 7alpha-methyl steroids
WO2003079961A2 (en) Method for producing 7$g(a)-methyl steroids
CA2193610A1 (en) 17 .alpha.-cyanomethylestra-4, 9-dien derivative compounds, processes for making same and pharmaceutical compositions containing same
CA2238690A1 (en) Method of preparing 21-alkylated pregna-1,4,16-trien-3,20-diones
AU4918697A (en) Method of preparing 21-alkylated pregna-1,4,16-trien-3,20-diones
HU196433B (en) Process for producing new 20-amino-steroides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010717

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020415